Wallace Pharmaceuticals Inc.

Manufacturer Details

There are currently no manufacturer details available.

Wallace Pharmaceuticals Inc. Drugs

Sun Therape Face Spf-35...

Sun Therape Face Spf-35

DOSAGE AND ADMINISTRATION: NOT FOR INHALATION OR INJECTION. SEE DIRECTIONS FOR USE.

The usual starting dose is as follows:

Adults and Adolescents (13 Years and Older): Two ampules four times daily, taken one-half hour before meals and at bedtime.

Children 2-12 Years: One ampule four times daily, taken one-half hour before meals and at bedtime.

Pediatric Patients Under 2 Years: Not recommended.

If satisfactory control of symptoms is not achieved within two to three weeks, the dosage may be increased but should not exceed 40 mg/kg/day.

Patients should be advised that the effect of Cromolyn Sodium, USP therapy is dependent upon its administration at regular intervals, as directed.

Maintenance Dose: Once a therapeutic response has been achieved, the dose may be reduced to the minimum required to maintain the patient with a lower degree of symptomatology. To prevent relapses, the dosage should be maintained.

Administration: Cromolyn Sodium, USP should be administered as a solution at least 1/2 hour before meals and at bedtime after preparation according to the following directions:
Break open ampule(s) and squeeze liquid contents of ampule(s) into a glass of water. Stir solution. Drink all of the liquid.
Azelastine Hydrochlorid...

Azelastine Hydrochloride Spray

2.1 Seasonal Allergic Rhinitis

     In children 6 to 11 years of age, the recommended dose of Azelastine Hydrochloride Nasal Spray 0.1% and 0.15% is 1 spray per nostril twice daily.

     In adults and adolescents 12 years of age and older, the recommended dose of Azelastine Hydrochloride Nasal Spray 0.1% and 0.15% is 1 or 2 sprays per nostril twice daily. Azelastine Hydrochloride Nasal Spray 0.15% may also be administered as 2 sprays per nostril once daily.

2.2 Perennial Allergic Rhinitis

     In children 6 to 11 years of age, the recommended dose of Azelastine Hydrochloride Nasal Spray 0.1% and 0.15% is 1 spray per nostril twice daily.

     In adults and adolescents 12 years of age and older, the recommended dose of Azelastine Hydrochloride Nasal Spray 0.15% is 2 sprays per nostril twice daily.

2.3 Important Administration Instructions

     Administer Azelastine Hydrochloride Nasal Spray by the intranasal route only.

     Priming: Prime Azelastine Hydrochloride Nasal Spray before initial use by releasing 6 sprays or until a fine mist appears. When Azelastine Hydrochloride Nasal Spray has not been used for 3 or more days, reprime with 2 sprays or until a fine mist appears. Avoid spraying Azelastine Hydrochloride Nasal Spray and into the eyes.
Felbamate

Felbamate

Felbamate has been studied as monotherapy and adjunctive therapy in adults and as adjunctive therapy in children with seizures associated with Lennox-Gastaut syndrome. As Felbamate is added to or substituted for existing AEDs, it is strongly recommended to reduce the dosage of those AEDs in the range of 20-33% to minimize side effects (see Drug Interactions subsection).

Dosage Adjustment in the Renally Impaired: Felbamate should be used with caution in patients with renal dysfunction. In the renally impaired, starting and maintenance doses should be reduced by one-half (see CLINICAL PHARMACOLOGY / Pharmacokinetics and PRECAUTIONS ). Adjunctive therapy with medications which affect felbamate plasma concentrations, especially AEDs, may warrant further reductions in felbamate daily doses in patients with renal dysfunction.

Adults (14 years of age and over) The majority of patients received 3600 mg/day in clinical trials evaluating its use as both monotherapy and adjunctive therapy.

Monotherapy: (Initial therapy) Felbamate has not been systematically evaluated as initial monotherapy. Initiate Felbamate at 1200 mg/day in divided doses three or four times daily. The prescriber is advised to titrate previously untreated patients under close clinical supervision, increasing the dosage in 600-mg increments every 2 weeks to 2400 mg/day based on clinical response and thereafter to 3600 mg/day if clinically indicated.

Conversion to Monotherapy: Initiate Felbamate at 1200 mg/day in divided doses three or four times daily. Reduce the dosage of concomitant AEDs by one-third at initiation of Felbamate therapy. At week 2, increase the Felbamate dosage to 2400 mg/day while reducing the dosage of other AEDs up to an additional one-third of their original dosage. At week 3, increase the Felbamate dosage up to 3600 mg/day and continue to reduce the dosage of other AEDs as clinically indicated.

Adjunctive Therapy: Felbamate should be added at 1200 mg/day in divided doses three or four times daily while reducing present AEDs by 20% in order to control plasma concentrations of concurrent phenytoin, valproic acid, phenobarbital, and carbamazepine and its metabolites. Further reductions of the concomitant AEDs dosage may be necessary to minimize side effects due to drug interactions. Increase the dosage of Felbamate by 1200 mg/day increments at weekly intervals to 3600 mg/day. Most side effects seen during Felbamate adjunctive therapy resolve as the dosage of concomitant AEDs is decreased.
Table 6 Dosage Table (adults) *See Adjunctive and Conversion to Monotherapy sections. Dosage reduction of concomitant AEDs WEEK 1 REDUCE original dose by20–33%* WEEK 2 REDUCE original dose byup to an additional 1/3* WEEK 3 REDUCE asclinicallyindicated FelbamateDosage 1200 mg/day Initial dose 2400 mg/dayTherapeutic dosage range 3600 mg/dayTherapeutic dosage range
While the above Felbamate conversion guidelines may result in a Felbamate 3600 mg/day dose within 3 weeks, in some patients titration to a 3600 mg/day Felbamate dose has been achieved in as little as 3 days with appropriate adjustment of other AEDs.

Children with Lennox-Gastaut Syndrome (Ages 2-14 years) Adjunctive Therapy: Felbamate should be added at 15 mg/kg/day in divided doses three or four times daily while reducing present AEDs by 20% in order to control plasma levels of concurrent phenytoin, valproic acid, phenobarbital, and carbamazepine and its metabolites. Further reductions of the concomitant AEDs dosage may be necessary to minimize side effects due to drug interactions. Increase the dosage of Felbamate by 15 mg/kg/day increments at weekly intervals to 45 mg/kg/day. Most side effects seen during Felbamate adjunctive therapy resolve as the dosage of concomitant AEDs is decreased.
Carisoprodol

Carisoprodol

The recommended dose of Carisoprodol is 250 mg to 350 mg three times a day and at bedtime. The recommended maximum duration of Carisoprodol use is up to two or three weeks.
Januvia

Januvia

DOSAGE AND ADMINISTRATION: NOT FOR INHALATION OR INJECTION. SEE DIRECTIONS FOR USE.

The usual starting dose is as follows:

Adults and Adolescents (13 Years and Older): Two ampules four times daily, taken one-half hour before meals and at bedtime.

Children 2-12 Years: One ampule four times daily, taken one-half hour before meals and at bedtime.

Pediatric Patients Under 2 Years: Not recommended.

If satisfactory control of symptoms is not achieved within two to three weeks, the dosage may be increased but should not exceed 40 mg/kg/day.

Patients should be advised that the effect of Cromolyn Sodium, USP therapy is dependent upon its administration at regular intervals, as directed.

Maintenance Dose: Once a therapeutic response has been achieved, the dose may be reduced to the minimum required to maintain the patient with a lower degree of symptomatology. To prevent relapses, the dosage should be maintained.

Administration: Cromolyn Sodium, USP should be administered as a solution at least 1/2 hour before meals and at bedtime after preparation according to the following directions:
Break open ampule(s) and squeeze liquid contents of ampule(s) into a glass of water. Stir solution. Drink all of the liquid.
Trilyte With Flavor Pac...

Trilyte With Flavor Packs

DOSAGE AND ADMINISTRATION: TRILYTE with flavor packs is usually administered orally, but may be given via nasogastric tube to patients who are unwilling or unable to drink the solution. Ideally, the patient should fast for approximately three or four hours prior to TRILYTE with flavor packs administration, but in no case should solid food be given for at least two hours before the solution is given.

Oral Administration: Adults: At a rate of 240 mL (8 oz.) every 10 minutes, until the rectal effluent is clear or 4 liters are consumed. Pediatric Patients (aged 6 months or greater): At a rate of 25 mL/kg/hour, until the rectal effluent is clear. Rapid drinking of each portion is preferred to drinking small amounts continuously. Nasogastric Tube Administration: Adults: At a rate of 20-30 mL per minute (1.2-1.8 liters per hour). Pediatric Patients (aged 6 months or greater): At a rate of 25 mL/kg/hour, until the rectal effluent is clear.

The first bowel movement should occur approximately one hour after the start of TRILYTE with flavor packs administration. Ingestion of 4 liters of TRILYTE with flavor packs solution prior to gastrointestinal examination produces satisfactory preparation in over 95% of patients.

Various regimens have been used. One method is to schedule patients for examination in midmorning or later, allowing the patients three hours for drinking and an additional one hour period for complete bowel evacuation. Another method is to administer TRILYTE with flavor packs on the evening before the examination.

Preparation of the Solution: This preparation can be used with or without the flavor packs. The pharmacist should dispense the bottle and the attached flavor packs to the patient.
To add flavor, tear open one flavor pack at the indicated marking and pour contents into the bottle BEFORE reconstitution. Discard unused flavor packs. SHAKE WELL to incorporate flavoring into the powder. Add tap water to FILL line marked 4 liters. Replace cap tightly and SHAKE WELL until all ingredients have dissolved. No additional ingredients, e.g., flavorings, should be added to the solution.
Note: If not using a flavor pack, omit steps one and two above.

Dissolution is facilitated by using lukewarm water. The solution is more palatable if chilled before administration. However, chilled solution is not recommended for infants. The reconstituted solution should be refrigerated and used with 48 hours. Discard any unused portion.
Azelastine Hydrochlorid...

Azelastine Hydrochloride Solution Drops

The recommended dose is one drop instilled into each affected eye twice a day.
Azelastine Hydrochlorid...

Azelastine Hydrochloride Spray

Seasonal Allergic Rhinitis

The recommended dose of Azelastine Hydrochloride Nasal Spray in adults and children 12 years and older with seasonal allergic rhinitis is one or two sprays per nostril twice daily. The recommended dose of Azelastine Hydrochloride Nasal Spray in children 5 years to 11 years of age is one spray per nostril twice daily.

Vasomotor Rhinitis

The recommended dose of Azelastine Hydrochloride Nasal Spray in adults and children 12 years and older with vasomotor rhinitis is two sprays per nostril twice daily.

Before initial use, the delivery system should be primed with 4 sprays or until a fine mist appears. When 3 or more days have elapsed since the last use, the pump should be reprimed with 2 sprays or until a fine mist appears.

CAUTION: Avoid spraying in the eyes.

Directions for Use: Illustrated patient instructions for proper use accompany each package of Azelastine Hydrochloride Nasal Spray.

Wallace Pharmaceuticals Inc.

Manufacturer Details

Share This Page

Wallace Pharmaceuticals Inc. Drugs